NO20063326L - Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse derav - Google Patents
Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse deravInfo
- Publication number
- NO20063326L NO20063326L NO20063326A NO20063326A NO20063326L NO 20063326 L NO20063326 L NO 20063326L NO 20063326 A NO20063326 A NO 20063326A NO 20063326 A NO20063326 A NO 20063326A NO 20063326 L NO20063326 L NO 20063326L
- Authority
- NO
- Norway
- Prior art keywords
- combination
- pyrimidinamine
- methylphenyl
- pyridyl
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- -1 4-methyl-piperazinomethyl Chemical group 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000032839 leukemia Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53156303P | 2003-12-19 | 2003-12-19 | |
| PCT/EP2004/014439 WO2005058320A1 (en) | 2003-12-19 | 2004-12-17 | COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063326L true NO20063326L (no) | 2006-09-19 |
Family
ID=34700180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063326A NO20063326L (no) | 2003-12-19 | 2006-07-18 | Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse derav |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080139480A1 (https=) |
| EP (1) | EP1696917A1 (https=) |
| JP (1) | JP2007514699A (https=) |
| KR (1) | KR20060125810A (https=) |
| CN (1) | CN1889952A (https=) |
| AU (2) | AU2004298761A1 (https=) |
| BR (1) | BRPI0417759A (https=) |
| CA (1) | CA2547196A1 (https=) |
| EC (1) | ECSP066656A (https=) |
| IL (1) | IL176070A0 (https=) |
| MA (1) | MA28240A1 (https=) |
| MX (1) | MXPA06006925A (https=) |
| NO (1) | NO20063326L (https=) |
| RU (1) | RU2006125741A (https=) |
| TN (1) | TNSN06182A1 (https=) |
| WO (1) | WO2005058320A1 (https=) |
| ZA (1) | ZA200603904B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8921403B2 (en) | 2007-08-31 | 2014-12-30 | Janssen Pharmaceutica, Nv | Combinations of imazalil and hydroxypyridones |
| WO2009036753A2 (de) * | 2007-09-20 | 2009-03-26 | Schebo Biotech Ag | Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie |
| US8575187B2 (en) | 2008-02-06 | 2013-11-05 | Janssen Pharmaceutica, Nv | Combinations of anilinopyrimidines and pyrion compounds |
| US8043422B2 (en) | 2008-02-06 | 2011-10-25 | Janssen Pharmaceutica, Nv | Combinations of phenylpyrroles and pyrion compounds |
| US20110212176A1 (en) * | 2008-10-31 | 2011-09-01 | University Health Network | Ciclopirox and cytarabine for the treatment of leukemic disorders |
| EP2576513A1 (en) * | 2010-06-01 | 2013-04-10 | Biotheryx Inc. | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
| AU2011261501B2 (en) * | 2010-06-01 | 2016-01-21 | Biotheryx, Inc. | Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone |
| CN102917591B (zh) | 2010-06-10 | 2014-07-23 | 詹森药业有限公司 | 嘧霉胺和单萜烯的组合 |
| ES2602481T3 (es) | 2010-07-01 | 2017-02-21 | Janssen Pharmaceutica, N.V. | Combinaciones antimicrobianas de compuestos de piriona con polietileniminas |
| CN103191110A (zh) * | 2013-03-28 | 2013-07-10 | 中国科学院昆明植物研究所 | 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8528983D0 (en) * | 1985-11-25 | 1986-01-02 | Ciba Geigy Ag | Use of chelating agents |
| EP0227593A1 (en) * | 1985-11-25 | 1987-07-01 | The Hospital For Sick Children | Use of chelating agents |
| MY129541A (en) * | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| MXPA03008192A (es) * | 2001-03-23 | 2004-01-29 | Enzon Inc | Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos. |
| AU2003251875A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
-
2004
- 2004-12-17 CA CA002547196A patent/CA2547196A1/en not_active Abandoned
- 2004-12-17 AU AU2004298761A patent/AU2004298761A1/en not_active Abandoned
- 2004-12-17 KR KR1020067012061A patent/KR20060125810A/ko not_active Withdrawn
- 2004-12-17 MX MXPA06006925A patent/MXPA06006925A/es not_active Application Discontinuation
- 2004-12-17 EP EP04804040A patent/EP1696917A1/en not_active Withdrawn
- 2004-12-17 RU RU2006125741/14A patent/RU2006125741A/ru not_active Application Discontinuation
- 2004-12-17 JP JP2006544368A patent/JP2007514699A/ja active Pending
- 2004-12-17 US US10/583,107 patent/US20080139480A1/en not_active Abandoned
- 2004-12-17 WO PCT/EP2004/014439 patent/WO2005058320A1/en not_active Ceased
- 2004-12-17 CN CNA2004800362740A patent/CN1889952A/zh active Pending
- 2004-12-17 BR BRPI0417759-2A patent/BRPI0417759A/pt not_active IP Right Cessation
-
2006
- 2006-05-16 ZA ZA200603904A patent/ZA200603904B/en unknown
- 2006-05-31 IL IL176070A patent/IL176070A0/en unknown
- 2006-06-15 TN TNP2006000182A patent/TNSN06182A1/en unknown
- 2006-06-19 EC EC2006006656A patent/ECSP066656A/es unknown
- 2006-06-26 MA MA29141A patent/MA28240A1/fr unknown
- 2006-07-18 NO NO20063326A patent/NO20063326L/no not_active Application Discontinuation
-
2009
- 2009-04-28 AU AU2009201694A patent/AU2009201694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004298761A1 (en) | 2005-06-30 |
| CA2547196A1 (en) | 2005-06-30 |
| WO2005058320A1 (en) | 2005-06-30 |
| MA28240A1 (fr) | 2006-10-02 |
| IL176070A0 (en) | 2006-10-05 |
| AU2009201694A1 (en) | 2009-05-28 |
| BRPI0417759A (pt) | 2007-04-10 |
| ECSP066656A (es) | 2006-10-25 |
| MXPA06006925A (es) | 2006-08-23 |
| RU2006125741A (ru) | 2008-01-27 |
| EP1696917A1 (en) | 2006-09-06 |
| KR20060125810A (ko) | 2006-12-06 |
| ZA200603904B (en) | 2007-09-26 |
| JP2007514699A (ja) | 2007-06-07 |
| US20080139480A1 (en) | 2008-06-12 |
| TNSN06182A1 (en) | 2007-11-15 |
| CN1889952A (zh) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20076323L (no) | Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat | |
| WO2002085857A3 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| NO20070453L (no) | Kondenserte heterocykliske kinase inhibitorer | |
| MX2007006204A (es) | Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa. | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| CY1112281T1 (el) | Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη | |
| DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| WO2002062763A3 (en) | Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| AU2003259521A1 (en) | Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia | |
| NO20063326L (no) | Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse derav | |
| NO20064771L (no) | 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer | |
| IS6925A (is) | Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns | |
| AU2003233946A1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases | |
| BRPI0411324A (pt) | composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes | |
| MX2021000094A (es) | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. | |
| WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
| ATE454153T1 (de) | 5-ht4 antagonisten zur behandlung von herzversagen | |
| WO2006012958A3 (en) | Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| IS8139A (is) | Notkun týrósínkínasatálma til að meðhöndla sykursýki | |
| ATE476183T1 (de) | Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer | |
| AU2016204119A1 (en) | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |